St. Jude Medical seesaws on FDA warning letter Wall Street Beat

A warning letter from the FDA to St. Jude Medical (NYSE:STJ) sent the St. Paul, Minn.-based medical device company’s stock on a seesaw ride yesterday and today.

STJ shares closed up 1.5% yesterday at $38.85 each after St. Jude revealed the warning letter, but closed down 1.2% today at $38.39 apiece.


Sign up to get our free newsletters delivered straight to your inbox

St. Jude shrugged off the formal warning letter, which followed a so-called "Form 483" from the federal watchdog agency detailing 11 problems with quality control and documentation procedures at the Sylmar facility.

"As previously disclosed by management on its 3rd-quarter earnings call on Oct. 17, 2012, this warning letter was expected," St. Jude said today in a regulatory filing. "The FDA letter notes that it will not grant requests for exportation certificates to foreign governments or approve pre-market approval applications for Class III devices to which the quality system regulation deviations are reasonably related until the violations have been corrected. The warning letter does not, however, identify any specific concerns regarding the performance of, or indicate the need for any field or other action regarding, the Riata ST Optim or Durata leads or any other St. Jude Medical product," according to the filing. "Accordingly, the Company will continue manufacturing and shipping product from the Sylmar facility and customer orders are not expected to be impacted while we work to resolve the FDA’s concerns."

Last week, CEO Daniel Starks spent considerable energy trying to reassure investors at the J.P. Morgan healthcare conference about the problems in Sylmar, explaining why the Durata line was a sure thing, and why the Riata lead recall and FDA warnings related to a St. Jude manufacturing plant were no threat to the company’s hold on the larger ICD market.

The SEC filing made the same points, saying that St. Jude "has taken the appropriate regulatory circumstances into account in managing its business and setting investor expectations and believes the FDA’s concerns can be resolved without a material impact on the company’s financial results."

A week after Starks hipped investors to the possibility of a Form 483 in October, St. Jude revealed that the FDA came through on the threat, issuing a heavily redacted copy of the missive. A much less censored version made headlines the following month, disclosing further detail about the 11 problems found in Sylmar during FDA inspections from Sept. 25 to Oct. 17, 2012.

 Endostim raises $9M

Endostim raised $9.1 million of a hoped for $12 million from backers in 12 states for its implantable gastro-esophageal reflux disease device.

Read more

 Covidien closes CV Ingenuity buyout
Covidien (NYSE:COV) said it closed its buyout of CV Ingenuity and its drug-coated balloon platform.
Read more

 Given Imaging is off the auction block

Given Imaging (NSDQ:GIVN) says it’s taken itself off the auction block, prompting Discount Investment Corp. to say it’s putting its 46% stake up for sale.
Read more

 Stereotaxis regains NASDAQ’s good graces

Stereotaxis (NSDQ:STXS) said the NASDAQ stock exchange let it off the hook after a June 2012 de-listing warning after its market capitalization slipped below $15 million. Nevertheless, STXS shares closed down 10.3% today at $2.34 apiece.
Read more

 Analysts’ ups and downs

  • Abbott (NYSE:ABT): Barclays Equity Research initiates with "equal weight" rating, $35 price target.
  • Boston Scientific (NYSE:BSX): Credit Suisse upgrades from "neutral" to "outperform" rating, raises price target from $6 to $7.50.
  • C.R. Bard (NYSE:BCR): Bank of America/Merrill Lynch upgrades from "neutral" to "buy" rating, $114 price target; Leerink Swann maintains "market perform" rating, raises price target to $110-$115 from $98-$99.
  • Cerner (NSDQ:CERN): Sterne Agee Group reiterates "buy" rating, raises price target from $90 to $96.
  • Edwards Lifesciences (NYSE:EW): Zacks upgrades from “underperform” to “neutral” rating, $98 price target.
  • Haemonetics (NYSE:HAE): Zacks upgrades from "neutral" to an "outperform" rating, $50 price target.
  • Intuitive Surgical (NSDQ:ISRG): Lazard Capital upgrades from "neutral" to "buy" rating, $600 price target.
  • Medtronic (NYSE:MDT): TheStreet reaffirms "buy" rating.
  • Mindray (NYSE:MR): Goldman Sachs upgrades from “neutral” to “buy” rating.
  • NeuralStem (AMEX:CUR): Aegis Capital Corp. reiterates "buy" rating, raises price target from $3.50 to $4.
  • NxStage Medical (NSDQ:NXTM): Zacks raises from “neutral” to “outperform” rating, $14 price target.
  • Sirona Dental Systems (NSDQ:SIRO): Goldman Sachs downgrades from "buy" to "neutral" rating, $67 price target.
  • St. Jude Medical (NYSE:STJ): Barclays Equity Research reiterates"overweight/neutral" rating, $48 price target; BMO Capital Markets downgrades from "outperform" to "market perform" rating, raises price target from $38 to $40; Jefferies maintains "hold’ rating, raises price target to $39.
  • Varian Medical (NYSE:VAR): Lazard downgrades from "buy" to "neutral" rating.
  • Zimmer (NYSE:ZMH): Lazard downgrades from "buy" to "neutral" rating.

RSS From Medical Design & Outsourcing

  • Teknor Apex to showcase wide range of PVC compounds for medical devices at Medtec China
    Building on its international leadership role as a supplier of medical-grade PVC compounds, Teknor Apex Company has developed flexible and rigid formulations that address the special needs of device manufacturers. The company will highlight these capabilities at Medtec China 2015. “Teknor Apex produces or markets medical-grade PVC compounds in China, Singapore, Europe, and the United […]
  • The Raspberry Pi eco-system goes interstellar with the new Raspberry Pi Sense HAT
    Newark element14 has globally launched the latest addition to the expanding ecosystem of Raspberry Pi accessories, the Raspberry Pi Sense HAT, as featured in the ‘Astro Pi’ space mission. The Sense HAT will enable enthusiasts to control the same hardware used in space. The Sense HAT attaches to the Raspberry Pi board, and can be […]
  • CommScope completes acquisition of TE Connectivity’s Telecom
    CommScope Holding Company, has completed its previously announced acquisition of TE Connectivity’s Telecom, Enterprise and Wireless businesses, a leader in fiber optic connectivity for wireline and wireless networks. The all-cash transaction, valued at approximately $3 billion, strengthens CommScope’s position as a leading communications infrastructure provider with deeper resources to meet the world’s growing demand for network […]
  • SPI awards IKO Prosthetic Creative System the Student Design International Design Excellence Award
    SPI: The Plastics Industry Trade Association congratulated IKO Prosthetic Creative System for winning the SPI Student Design Award, part of the Industrial Designers Society of America’s (IDSA’s) International Design Excellence Awards (IDEA) program. The award was presented to IKO, an innovative, youth-focused prosthetic design company led by Chicago-based designer Carlos Torres, by SPI’s Senior Director of […]
  • New assay could revolutionize diagnosis and treatment of life-threatening disease
    Invasive Fungal Disease (IFD) is an emerging global health problem associated with high mortality rates in severely immunocompromised patients, such as those undergoing intensive chemotherapy or stem cell transplantation, and in patients suffering immune compromising conditions such as AIDS. The most common causative agents of this disease have been identified as Candida and Aspergillus species, […]
  • Molex delivers ISO 13485-compliant, medical-grade surgical cables from its class 100,000 clean room facility
    Molex, LLC operates a fully ISO 146441-1:1999 Class 8-certified clean room, satisfying strict particulate contamination levels specified by ISO-compliant requirements. Located in Thailand, the facility has less than 100,000 particulates (≥0.5µm) per cubic foot of air and manufactures a variety of ISO 13485-compliant medical cables and surgical cables used in operating theatres, hospitals, laboratories and […]
  • Swept-Source OCT: Patent license agreement between Massachusetts General Hospital and Heidelberg Engineering
    Heidelberg Engineering has entered into a patent license agreement with Massachusetts General Hospital (MGH) in Boston. The agreement grants global and exclusive rights to 77 basic patents and patent applications which relate to swept-source OCT technology and its application in ophthalmology. Spectral domain OCT has become indispensable to eye care professionals worldwide to diagnose and […]
  • MIT’s MultiFab presents a stark challenge to incumbent 3D Printer manufacturers’ hardware, software, and business Models
    MIT’s Computational Fabrication Group recently announced the MultiFab, a low-cost 3D printer that can combine up to 10 different resins in one part and also includes a 3D scanning system to identify and fix errors during production. According to Lux Research, these capabilities are rare in commercial 3D printers today due to the manufacturers’ need […]
  • AVX releases Accu-P MP medical grade film chip capacitors for medical devices
    AVX Corporation, a leading manufacturer of passive components and interconnect solutions, has released a new series of thin film chip capacitors specifically designed to meet the demanding performance specifications for implantable medical devices. Delivering extremely tight capacitive tolerances, exceptionally repeatable performance, and remarkably low ESR and high Q at high frequencies—including VHF, UHF, and RF […]
  • RIVANNA commences manufacturing of its Accuro device
    Rivanna Medical announced that it has begun manufacturing its FDA-cleared Accuro device, a handheld and untethered smart-phone-sized device that is designed to guide spinal anesthesia with automated 3D navigation technology in addition to ultrasound imaging of abdominal, musculoskeletal, cardiac and peripheral vascular anatomies. The product will be launched at the ASA annual meeting in San […]
  • FDA seeks public input on Quality Metrics guidance
    by Oliver Wolf, Senior Product Manager, MasterControl In line with the general shift towards risk-driven approaches in the quality management world, FDA is now taking steps towards applying those same principles to its own auditing schedule. At the end of July, the Center for Drug Evaluation and Research (CDER) and the Center for Biologics Evaluation […]

Leave a Reply